IMPUF vs. CAPR

Last updated Jun 4, 2026

IMPUF (Impala Platinum Holdings Ltd) and CAPR (Capricor Therapeutics, Inc.) are both stocks. IMPUF operates in Other Precious Metals & Mining (Basic Materials), while CAPR operates in Biotechnology (Healthcare). Over the past 5 years, IMPUF returned -1.71%/yr vs 48.25%/yr for CAPR. At a 0.03 correlation, their price movements are largely independent.

Performance

IMPUF vs. CAPR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Impala Platinum Holdings Ltd (IMPUF) and Capricor Therapeutics, Inc. (CAPR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, IMPUF achieves a -11.27% return, which is significantly lower than CAPR's -4.23% return.

IMPUF

• 1D: -1.10%
• 1M: -2.86%
• YTD: -11.27%
• 6M: 20.64%
• 1Y: 91.01%
• 3Y*: 18.89%
• 5Y*: -1.71%
• 10Y*: —

CAPR

• 1D: 1.10%
• 1M: -17.49%
• YTD: -4.23%
• 6M: -7.74%
• 1Y: 147.89%
• 3Y*: 82.46%
• 5Y*: 48.25%
• 10Y*: -1.55%

*Multi-year figures are annualized to reflect compound growth (CAGR)

IMPUF vs. CAPR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
IMPUF Impala Platinum Holdings Ltd	-11.27%	200.45%	12.15%	-60.02%	-5.41%	12.03%	50.30%	410.99%
CAPR Capricor Therapeutics, Inc.	-4.23%	109.13%	182.21%	26.68%	31.74%	-14.58%	167.97%	-70.91%

Correlation

The correlation between IMPUF and CAPR is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.12
Correlation (3Y) Calculated over the trailing 3-year period	0.04
Correlation (5Y) Calculated over the trailing 5-year period	0.04
Correlation (All Time) Calculated using the full available price history since Feb 26, 2019	0.03

Fundamentals

Market Cap IMPUF : $12.15B CAPR : $1.59B
EPS IMPUF : -$9.66 CAPR : -$2.32
PB Ratio IMPUF : 0.13 CAPR : 0.01
Total Revenue (TTM) IMPUF : $188.26B CAPR : $0.00
Gross Profit (TTM) IMPUF : $17.78B CAPR : -$42.41M
EBITDA (TTM) IMPUF : $29.69B CAPR : -$117.24M

Return for Risk

IMPUF vs. CAPR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMPUF

IMPUF Risk / Return Rank: 77
IMPUF Sharpe Ratio Rank: 76
IMPUF Sortino Ratio Rank: 74
IMPUF Omega Ratio Rank: 84
IMPUF Calmar Ratio Rank: 76
IMPUF Martin Ratio Rank: 74

CAPR

CAPR Risk / Return Rank: 79
CAPR Sharpe Ratio Rank: 54
CAPR Sortino Ratio Rank: 97
CAPR Omega Ratio Rank: 97
CAPR Calmar Ratio Rank: 76
CAPR Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IMPUF vs. CAPR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Impala Platinum Holdings Ltd (IMPUF) and Capricor Therapeutics, Inc. (CAPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IMPUF	CAPR	Difference
Sharpe ratio: Return per unit of total volatility	1.18	0.39	+0.79
Sortino ratio: Return per unit of downside risk	1.95	4.93	-2.98
Omega ratio: Gain probability vs. loss probability	1.35	1.66	-0.31
Calmar ratio: Return relative to maximum drawdown	2.13	2.20	-0.06
Martin ratio: Return relative to average drawdown	4.45	4.14	+0.31
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

IMPUF vs. CAPR - Sharpe Ratio Comparison

The current IMPUF Sharpe Ratio is 1.18, which is higher than the CAPR Sharpe Ratio of 0.39. The chart below compares the historical Sharpe Ratios of IMPUF and CAPR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	IMPUF	CAPR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.18	0.39	+0.79
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.03	0.26	-0.28
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.01	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.43	-0.08	+0.51

Drawdowns

IMPUF vs. CAPR - Drawdown Comparison

The maximum IMPUF drawdown since its inception was -80.80%, smaller than the maximum CAPR drawdown of -99.97%. Use the drawdown chart below to compare losses from any high point for IMPUF and CAPR.

Drawdown Indicators

	IMPUF	CAPR	Difference
Max Drawdown Largest peak-to-trough decline	-80.80%	-99.97%	+19.17%
Max Drawdown (1Y) Largest decline over 1 year	-42.87%	-67.67%	+24.80%
Max Drawdown (3Y) Largest decline over 3 years	-59.31%	-79.08%	+19.77%
Max Drawdown (5Y) Largest decline over 5 years	-79.84%	-79.08%	-0.76%
Max Drawdown (10Y) Largest decline over 10 years	—	-98.02%	—
Current Drawdown Current decline from peak	-39.20%	-99.15%	+59.95%
Average Drawdown Average peak-to-trough decline	-41.79%	-90.24%	+48.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.51%	35.87%	-15.36%

Volatility

IMPUF vs. CAPR - Volatility Comparison

The current volatility for Impala Platinum Holdings Ltd (IMPUF) is 17.55%, while Capricor Therapeutics, Inc. (CAPR) has a volatility of 18.51%. This indicates that IMPUF experiences smaller price fluctuations and is considered to be less risky than CAPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IMPUF	CAPR	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.55%	18.51%	-0.96%
Volatility (6M) Calculated over the trailing 6-month period	61.16%	163.76%	-102.60%
Volatility (1Y) Calculated over the trailing 1-year period	77.74%	384.80%	-307.06%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.06%	190.11%	-126.05%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	107.33%	179.88%	-72.55%

Dividends

IMPUF vs. CAPR - Dividend Comparison

IMPUF's dividend yield for the trailing twelve months is around 1.78%, while CAPR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020
CAPR Capricor Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
IMPUF Impala Platinum Holdings Ltd	1.78%	0.00%	0.00%	6.80%	7.85%	10.80%	1.75%

Financials

Frequently Asked Questions

Can I hold both IMPUF and CAPR in my portfolio?

IMPUF and CAPR have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, IMPUF or CAPR?

CAPR has higher volatility (18.51%) compared to IMPUF (17.55%). In terms of maximum drawdown, IMPUF dropped -80.80% vs CAPR's -99.97%.

Which has better risk-adjusted returns?

IMPUF currently has the higher Sharpe Ratio (1.18 vs 0.39), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.